{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-25-000091","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.721504+00:00","generated_at":"2026-05-22T13:19:09.579218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcutis Q1 product revenue $63.8M (+196% YoY); net loss narrows; appoints new CFO","bullets":["Net product revenue $63.8M, up 196% YoY; down 2% QoQ due to deductible resets.","Net loss $25.1M ($0.20/shr) vs $35.4M ($0.32/shr) YoY improvement.","Latha Vairavan appointed CFO effective May 6, 2025.","Patent litigation against Padagis stayed; all deadlines cancelled; 30-month extension.","PDUFA May 22 for ZORYVE foam 0.3% for scalp/body psoriasis; sNDA for cream 0.05% with PDUFA Oct 13."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-25-000091","json":"https://secwatch.observer/filing/0001787306-25-000091.json","markdown":"https://secwatch.observer/filing/0001787306-25-000091.md","text":"https://secwatch.observer/filing/0001787306-25-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/0001787306-25-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/arqt-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T13:19:09.579218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}